Treatment Clinical Trials for Testicular Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for testicular cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 32
1 2 Next >

  • Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

    This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 724 locations

  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors

    This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 289 locations

  • Paclitaxel, Ifosfamide and Cisplatin or Bleomycin Sulfate, Etoposide and Cisplatin in Treating Patients with Previously Untreated Intermediate- or Poor-Risk Germ Cell Tumors

    This randomized phase II trial studies how well paclitaxel, ifosfamide and cisplatin or bleomycin sulfate, etoposide and cisplatin work in treating patients with previously untreated intermediate- or poor-risk germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, bleomycin sulfate, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether paclitaxel, ifosfamide, and cisplatin or bleomycin sulfate, etoposide, and cisplatin is more effective in treating patients with intermediate- or poor-risk germ cell tumors.
    Location: 12 locations

  • Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

    This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
    Location: 11 locations

  • A Study of Nivolumab in Relapsed / Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed / Refractory Primary Testicular Lymphoma (PTL)

    The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed / Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed / Refractory Primary Testicular Lymphoma (PTL)
    Location: 10 locations

  • Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

    The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose / recommended Phase 2 dose, and efficacy of PLX7486.
    Location: 5 locations

  • Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy

    This phase I / II trial studies the side effects and best dose of cytotoxic T-lymphocytes and to see how well they work in treating patients with a hematologic cancer that is positive for Epstein-Barr virus. Vaccines made from a patient or donor's white blood cells may help the body build an effective immune response to kill cancer cells.
    Location: 5 locations

  • Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas

    This phase I / II trial studies the side effects and best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with untreated large B-cell lymphoma, diffuse large B-cell lymphoma or gray zone lymphomas. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells.
    Location: 4 locations

  • T-Lymphocytes in Treating Patients with Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and the best dose of laboratory-treated T lymphocytes in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that is active or has returned after a period of improvement. Giving an infusion of a person's T lymphocytes that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells.
    Location: 3 locations

  • Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma

    This phase I trial studies the side effects of laboratory-treated T cells in treating patients with B-cell chronic lymphocytic leukemia, B-cell lymphoma, or multiple myeloma that has come back or has not gone away after treatment. This study combines two different ways of fighting disease, antibodies (proteins that protect the body from bacterial and other diseases) and T cells (special infection-fighting blood cells that can kill other cells, including cancer cells). Treating the T cells in the laboratory by adding an antibody may help the T cells last longer in the body and kill more cancer cells.
    Location: 3 locations

  • Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant

    This phase I / II trial studies the side effects and best dose of multi-virus-specific donor T cells to see how well it works in treating patients with B cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma who have undergone donor stem cell transplant. Biological therapies may stimulate the immune system in different ways and stop cancer cells from growing. By joining an antibody to the donor T cells that recognize the viruses, it may be able to make the cell that can last a long time in the body, provide protection from viruses, and recognize and kill leukemia.
    Location: 3 locations

  • Genetically Modified T Cells in Treating Patients With B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

    The purpose of this study is to find the biggest dose of chimeric T cells that is safe, to see how the T cell with each sort of chimeric receptor lasts, to learn what the side effects are and to see whether this therapy might help people with lymphoma or chronic lymphocytic leukemia (CLL).
    Location: 3 locations

  • Autologous or Donor Cytotoxic T-Cells in Treating Patients With Epstein-Barr Virus-Positive Lymphoma, Lymphoepithelioma, or Lymphoproliferative Disorder

    The purpose of this study is to find the largest safe dose of transforming growth factor-beta (TGFb) resistant latent membrane protein (LMP)-specific cytotoxic T cells, to learn what the side effects are and to see whether this therapy might help patients with Hodgkin disease, non-Hodgkin lymphoma and lymphoepithelioma.
    Location: 3 locations

  • Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Germ Cell Tumors

    This phase II trial studies how well brentuximab vedotin works in treating patients with germ cell tumors that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread.
    Location: 2 locations

  • Pembrolizumab in Treating Patients with Relapsed and Refractory Gray-Zone Lymphoma, Primary Central Nervous System Lymphoma, or Other Extra-Nodal Diffuse Large B-Cell Lymphomas

    This phase II trial studies how well pembrolizumab works in treating patients with gray-zone lymphoma, primary central nervous system lymphoma, or other extra-nodal diffuse large B-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Retroperitoneal Lymph Node Dissection in Treating Patients with Stage I-IIA Testicular Seminoma

    This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

    This phase I / II trial studies the side effects and best dose of azacitidine when given together with romidepsin and to see how well they work in treating patients with relapsed or refractory lymphoid malignancies. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with romidepsin may be an effective treatment for lymphoid malignancies.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma

    This phase I trial studies the side effects and the best dose of genetically modified T-cells in treating patients with advanced non-Hodgkin's lymphoma. Biological therapies, such as genetically modified T-cells may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Sirolimus, Cyclophosphamide, and Topotecan Hydrochloride in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphomas

    This phase I trial studies the side effects and best dose of sirolimus and cyclophosphamide when given together with topotecan hydrochloride in treating children and young adults with relapsed or refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as sirolimus and cyclophosphamide, work in different way to stop the growth of tumor cells, either by killing them or stop them from dividing. Topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sirolimus together with cyclophosphamide and topotecan hydrochloride may kill more tumor cells.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.

    This phase I trial studies the side effects and best dose of modified T-cells in treating patients with Epstein-Barr virus positive lymphoma. Some types of lymphoma or lymphoproliferative disease are associated with Epstein-Barr virus. White blood cells that are treated in the laboratory with Epstein-Barr virus may be an effective treatment for lymphoma or lymphoproliferative disease.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Diseases

    The purpose of this study is to obtain some of the donor's blood to make latent membrane protein (LMP)-specific cytotoxic T-lymphocytes (CTLs) so they would be available to potentially treat a recipient who had cancer of other disease associated with Epstein-Barr virus (EBV).
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Laboratory-Treated T Lymphocytes in Treating Patients With Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and the best dose of laboratory-treated T lymphocytes in treating patients with Hodgkin lymphoma and Non-Hodgkin Lymphoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • High-Dose Chemotherapy, Bevacizumab, and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors

    This phase II trial studies how well high-dose chemotherapy, bevacizumab, and stem cell transplant work in treating patients with germ cell tumors that have come back. Giving chemotherapy before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. Also, monoclonal antibodies, such as bevacizumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vorinostat, Niacinamide, and Etoposide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

    This phase I trial studies the side effects and best doses of niacinamide and etoposide with vorinostat in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma. Vorinostat and niacinamide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Vorinostat and niacinamide may help etoposide work better by making cancer cells more sensitive to the drug.
    Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

  • Donor Peripheral Blood Stem Cell or Bone Marrow Transplant in Treating Patients With Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    This clinical trial studies donor peripheral blood stem cell or bone marrow transplant in treating patients with lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation (TBI) before a donor peripheral blood stem cell (PBSC) or bone marrow transplant (BMT) helps stop the growth of cancer cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota


1 2 Next >